Jump to any asset
850 assets, updated daily
As of September 11, 2026, Viking Therapeutics, Inc. (VKTX) trades at $32.13. CleaRank Financial AI rates it Buy with a fair value of $32.13, in line with the current price. Wall Street's consensus target is $95.00 across 20 analysts. RSI at 39 is in neutral territory, and the price is below its 50-day average of $35.07.
Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. NASDAQ
$32.13
-0.5700 (-1.74%)
Latest Price
AI Analyst Consensus
79 / 100
Viking Therapeutics (VKTX) is currently trading at $32.13, below its 50-day and 200-day moving averages ($35.07 and $33.45), signaling a bearish technical trend. Despite this, Wall Street maintains a strong conviction with a consensus rating of 'Buy' and a median price target of $95, suggesting an upside of 195.7%. The company's recent earnings have shown mixed results, with a beat in the latest quarter but a significant miss in April 2026. Insider activity indicates a net seller position, with total sales of $23.2 million against purchases of $179.9 thousand, reflecting a moderate sell signal.
VKTX Price Analysis
Market Metrics
Open
$32.50
Day Range
$31.87 to $32.65
Prev Close
$32.70
Volume
1.71M
52-Week Range
$22.96 to $43.15
Market Cap
$3.75B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
VKTX Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, VKTX beat estimates 3 times. However, the stock fell 2 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
VKTX Analysis
Company's Health
3/5
AI Technical Analysis
Viking Therapeutics' stock is currently trading below its key moving averages, with its price below the 50-day SMA of $35.07 and the 200-day SMA of $33.45. The Relative Strength Index (RSI) is at 39.16, indicating bearish momentum. The MACD is also below its signal line, reinforcing the negative short-term trend. Volume on the latest trading day was slightly below its average, suggesting a lack of strong conviction from buyers at current levels. Key resistance is now seen at the 50-day SMA, while support levels are less defined given the current downtrend.
ProTips
- Monitor upcoming clinical trial data releases for Viking Therapeutics, as positive results are key catalysts for the stock's valuation.
- Given the current bearish technical trend, consider waiting for a confirmed upward price momentum or a break above the 50-day SMA before initiating new positions.
- The significant insider selling warrants attention; track any future insider transactions for shifts in management sentiment.
Key Catalysts
Bullish
Positive Clinical Trial Data
Positive results from ongoing clinical trials for Viking Therapeutics' drug candidates could significantly boost investor confidence and drive the stock price towards analyst targets.
Source: Company Pipeline UpdatesBullish
Analyst Price Target Upside
The median Wall Street price target of $95 represents a 195.7% upside from the current stock price, indicating strong potential for capital appreciation if the company meets expectations.
Source: Wall Street ResearchBearish
Moderate Insider Selling Signal
Recent insider transactions show net selling totaling $23.2 million against only $179.9 thousand in purchases, indicating a moderate sell signal from company insiders.
Source: Insider TransactionsBearish
Bearish Technical Momentum
The stock is trading below its 50-day and 200-day moving averages ($35.07 and $33.45), with RSI below 40, suggesting continued downward pressure in the short term.
Source: Technical AnalysisMarket Outlook
The outlook for Viking Therapeutics is cautiously optimistic, driven by strong analyst conviction and a median price target of $95, implying substantial upside from the current $32.13. This target suggests that the market is pricing in significant future growth, likely from the company's drug pipeline. The company's ability to execute on its clinical development and achieve regulatory approvals will be paramount to realizing this potential. However, near-term headwinds exist, including bearish technical indicators and notable insider selling. Investors should monitor upcoming clinical trial results and regulatory updates closely, as positive developments could catalyze a move towards the analyst targets, while setbacks could lead to further downside pressure.
Key Statistics
| Market Cap | 3.75B |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -4.67 |
| Dividend Yield | 0.00% |
| 52 Week High | 43.15 |
| 52 Week Low | 22.96 |
Viking Therapeutics operates in the Biotechnology sector, which has a median P/E ratio of -6.88 (negative, reflects current losses) and median revenue growth of 8.1%. The company's own revenue growth is not provided, and its EPS is negative (-$4.67), making traditional P/E ratio analysis inapplicable. The lack of positive revenue growth and negative EPS suggest the company is in a growth or development phase, relying on future pipeline success for valuation. The current price of $32.13 does not appear to be supported by current fundamental metrics, but the significant upside potential indicated by analyst targets suggests market expectations are heavily weighted towards future pipeline developments.
Earnings & Growth Analysis
Viking Therapeutics' recent earnings reports show a mixed performance. The company reported an EPS of $0.89 in the latest quarter (July 2026), beating estimates by 2.3%, though the stock saw a 1.27% decline. Prior to this, a significant miss occurred in April 2026 with an EPS of -$1.37 against an estimate of -$0.91. While the most recent quarter showed a slight beat, the overall earnings trajectory has been inconsistent, with a substantial miss in Q2 2026 and a beat in Q1 2026. Revenue estimates for upcoming quarters are currently reported as $0.
Key Risks
The primary risks for Viking Therapeutics include the significant insider selling activity, with over $23 million in sales against minimal purchases, signaling a moderate sell signal from management. The stock's current bearish technical momentum, trading below key moving averages, also presents a near-term risk. Also, the company's negative EPS and lack of reported revenue growth indicate a reliance on future pipeline success, which carries inherent clinical and regulatory risks.
Technical Indicators
| RSI (14) | 39.16 |
|---|---|
| MACD | -0.34 |
| SMA 50 | 35.07 |
| SMA 200 | 33.45 |
RSI
Bearish
SMA Cross
Bullish
Price vs SMA
Bearish
MACD
Bearish
Golden Cross in effect with the 50-day SMA ($35.07) above the 200-day SMA ($33.45), price is trading below the 50-day SMA.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.31
Weak correlation
Nasdaq 100 (QQQ)
+0.30
Weak correlation
Bitcoin (BTC)
+0.17
Weak correlation
Gold (XAU)
+0.08
Weak correlation
Check Custom Correlation
Calculating correlation...
VKTX Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
🟢 LONG ENTRY (click to switch)
CONSERVATIVE
$31.49
2% below current price (Pullback entry)
Lower risk, wait for pullback
AGGRESSIVE
$32.13
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$30.18
MAX LOSS
-4.1%
Volatility-Adjusted Stop Loss
Calculated based on RSI (39.2) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$33.06
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$34.64
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$36.21
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for VKTX is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 11, 2026.Growth of $10,000
A $10,000 investment in VKTX in September 2016 would be worth about $245,267 today, compared with about $35,030 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in VKTX today could grow to about $48,932 by 2036 in the base case, with a bull case near $371,226 and a bear case around $6,450. Projections are statistical simulations, not guarantees.
VKTX Stock Price Prediction: 2030
CleaRank's simulation projects a price near $60.64 for VKTX by 2030 in the base case, from $32.13 today (1.9x over 4 years). The downside path ends near $16.83. These are outcomes of a Monte Carlo simulation run on VKTX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $19.84 | $37.66 | $71.48 |
| 2028 | $17.83 | $44.14 | $109 |
| 2029 | $17.05 | $51.74 | $157 |
| 2030 | $16.83 | $60.64 | $218 |
| 2031 | $16.96 | $71.07 | $298 |
| 2032 | $17.34 | $83.30 | $400 |
| 2033 | $17.92 | $97.64 | $532 |
| 2034 | $18.68 | $114 | $701 |
| 2035 | $19.62 | $134 | $917 |
| 2036 | $20.72 | $157 | $1,193 |
Method: 10,000 simulated price paths using VKTX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. VKTX is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
VKTX Insider Trading Analysis
Bought
$179.9K
2 Transactions
Sold
$23.2M
14 Transactions
Insiders
10
Active Traders
Avg Transaction
$1.5M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 1, 2024 | MANCINI MARIANNA
Chief Operating Officer
|
Sell | 281.4K | $22.1M |
| Sep 20, 2024 | LIAN BRIAN
Chief Executive Officer
|
Sell | 216.1K | $15.3M |
| Oct 28, 2024 | ZANTE GREGORY S
Chief Financial Officer
|
Sell | 131.7K | $10.1M |
| Jan 6, 2025 | LIAN BRIAN
Chief Executive Officer
|
Sell | 194.5K | $8.3M |
| Jan 5, 2026 | LIAN BRIAN
Chief Executive Officer
|
Sell | 233.4K | $7.7M |
| Aug 19, 2024 | LIAN BRIAN
Chief Executive Officer
|
Sell | 112.9K | $7.4M |
| Feb 8, 2024 | LIAN BRIAN
Chief Executive Officer
|
Sell | 269.1K | $7.2M |
| Jul 30, 2024 | LIAN BRIAN
Chief Executive Officer
|
Sell | 115.9K | $6.7M |
| May 3, 2024 | ZANTE GREGORY S
Chief Financial Officer
|
Sell | 66.8K | $5.0M |
| Jul 29, 2026 | LIAN BRIAN
Chief Executive Officer
|
Sell | 148.5K | $4.9M |
Page 1 of 1
Frequently Asked Questions
What is Viking Therapeutics' (VKTX) stock price forecast for 2030?
Based on Monte Carlo simulations, Viking Therapeutics' stock price is projected to be $60.64 in 2030 under a base case scenario. The downside projection is $16.83, while the upside projection reaches $218.44. These figures represent statistical outcomes and are not definitive price targets.
Is VKTX stock a buy right now?
Viking Therapeutics (VKTX) is rated a 'Buy' by Wall Street analysts, with a consensus score of 79 out of 100. The median analyst price target is $95, suggesting a potential upside of 195.7% from the current price of $32.13.
What are the main risks facing Viking Therapeutics?
Key risks for VKTX include significant insider selling totaling over $23 million, bearish technical indicators with the stock trading below its 50-day and 200-day moving averages ($35.07 and $33.45), and the company's current negative EPS and lack of reported revenue growth.
How has Viking Therapeutics performed in recent earnings reports?
Viking Therapeutics reported an EPS beat in its latest quarter (July 2026) at $0.89 versus an estimate of $0.87, but the stock declined. Previous quarters showed a significant EPS miss in April 2026 and a beat in March 2026, indicating inconsistent earnings performance.
What is the technical outlook for VKTX stock?
The technical outlook for VKTX is currently bearish, with the stock trading below its 50-day and 200-day moving averages ($35.07 and $33.45) and exhibiting bearish momentum according to the RSI and MACD indicators.
How does VKTX compare to its sector averages?
Viking Therapeutics operates in the Healthcare sector, which has a median P/E of -6.88 and median revenue growth of 8.1%.
What is the consensus rating for Viking Therapeutics stock?
The consensus rating for Viking Therapeutics (VKTX) among Wall Street analysts is 'Buy', with a total of 20 analysts covering the stock. The overall Wall Street score is 79 out of 100.